Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1621 AL 1635

Case report: recurrent parkinsonism-hyperpyrexia syndrome following discontinuation of subthalamic deep brain stimulation

Kadowaki T, Hashimoto K, Suzuki K, Watanabe Y, Hirata K.

Mov Disord. 2011 Jul;26(8):1561-2. doi: 10.1002/mds.23596. Epub 2011 Mar 29.

2-{[4-(4-[(125)I]Iodobenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol

Chopra A.

2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

N-((E)-4-[(18)F]Fluorobut-2-en-1-yl)-2β-carbomethoxy-3β-(4'-fluorophenyl)nortropane

Stehouwer JS, Chopra A.

2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

N-{2-[4-(4-[(125)I]Iodobenzyl)-piperidin-1-ylmethyl]benzoimidazol-5-yl}-methanesulfonamide

Chopra A.

2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

Risk factors for aspiration pneumonia in frail older people: a systematic literature review

van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, Schols JM, de Baat C.

J Am Med Dir Assoc. 2011 Jun;12(5):344-54. doi: 10.1016/j.jamda.2010.12.099. Epub 2011 Mar 21.

Melatonin and aging: prospects for human treatment

Bubenik GA, Konturek SJ.

J Physiol Pharmacol. 2011 Feb;62(1):13-9.

Distribution, level, pharmacology, regulation, and signaling of 5-HT6 receptors in rats and marmosets with special reference to an experimental model of parkinsonism

Zhang X, Andren PE, Glennon RA, Svenningsson P.

J Comp Neurol. 2011 Jun 15;519(9):1816-27. doi: 10.1002/cne.22605.

Cell based therapies in Parkinson's Disease

Behari M, Singhal KK.

Ann Neurosci. 2011 Apr;18(2):76-83. doi: 10.5214/ans.0972.7531.1118209.

Safety of rasagiline for the treatment of Parkinson's disease

Perez-Lloret S, Rascol O.

Expert Opin Drug Saf. 2011 Jul;10(4):633-43. doi: 10.1517/14740338.2011.573784. Epub 2011 Apr 1.

Adeno-Associated Virus (AAV) Vectors in the CNS

McCown TJ.

Curr Gene Ther. 2011 Jun;11(3):181-8. doi: 10.2174/156652311795684759.

Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population

Iwamoto J, Takeda T, Matsumoto H.

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1.

Correlates of care relationship mutuality among carers of people with Alzheimer's and Parkinson's disease

Shim B, Landerman LR, Davis LL.

J Adv Nurs. 2011 Aug;67(8):1729-38. doi: 10.1111/j.1365-2648.2011.05618.x. Epub 2011 Apr 4.

Parkinsonism in patients with cirrhosis: coincidence or consequence?

Weissenborn K.

Liver Int. 2011 May;31(5):592-4. doi: 10.1111/j.1478-3231.2011.02470.x. Epub 2011 Feb 15.

Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers

Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, Lyons KE, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS.

Parkinsonism Relat Disord. 2011 Jul;17(6):440-5. doi: 10.1016/j.parkreldis.2011.03.002. Epub 2011 Apr 1.

Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease

Hicks CW, Pandya MM, Itin I, Fernandez HH.

Parkinsonism Relat Disord. 2011 Jun;17(5):379-81. doi: 10.1016/j.parkreldis.2011.03.003. Epub 2011 Apr 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias